



Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Figure 1. (A) Overall survival estimates by Kaplan-Meier analysis and (B) cause of death in PTX-coated vs bare nitinol stent (BNS) groups. PTX, paclitaxel.



Supplementary Figure 2. (A) Overall survival estimates by Kaplan-Meier analysis and (B) cause of death in PTX-coated vs angioplasty groups. PTX, paclitaxel.



Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions

Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 1. Baseline Characteristics of the Study Population Before and After Matching in the PTX-Coated vs Bare Nitinol Stent Groups.^a

	Overall Population				Matched Population		
	PTX-Coated (n=285)	BNS (n=873)	Std Diff, %	p	PTX-Coated (n=281)	BNS (n=855)	Std Diff, %
Men	74.7	71.4	7.6	0.29	74.4	73.1	2.9
Age, y	73±8	73±9	2.3	0.73	73±8	73±9	0.5
Body mass index, kg/m ²	22.5±3.3	22.6±3.3	2.0	0.77	22.5±3.3	22.5±3.3	1.1
Hypertension	80.7	85.1	11.7	0.09	81.5	83.0	3.9
Diabetes mellitus	57.9	52.5	10.9	0.12	58.0	56.9	2.2
Dyslipidemia	58.9	55.1	7.8	0.27	58.4	57.9	0.9
Smoking	42.5	42.2	0.6	0.95	42.7	43.4	1.4
Chronic renal failure ^b	27.5	29.0	3.4	0.65	27.0	27.9	1.8
(missing data)	0.4	0.0	8.4	0.25	0.0	0.0	0.0
Regular dialysis	19.6	22.7	7.4	0.32	19.6	20.6	2.7
Aspirin use	91.9	90.3	5.9	0.48	91.8	92.1	1.0
Thienopyridine use	84.6	72.4	29.9	<0.001	84.3	84.1	0.6
Cilostazol use	26.7	33.3	14.6	0.040	26.7	26.7	0.1
Anticoagulant use	10.2	14.7	13.6	0.058	10.0	10.1	0.6
Rutherford category				0.072			
2	33.0	28.8	9.2		32.7	32.3	1.0
3	61.4	62.5	2.3		61.6	62.0	0.8
4	5.6	8.7	12.0		5.7	5.7	0.2
Ankle-brachial index	0.62±0.21	0.64±0.21	8.3	0.22	0.62±0.21	0.62±0.21	0.8
(missing data)	0.7	0.1	9.2	0.15	0.4	0.4	0.0
TASC II classification				0.12			
A	35.4	30.7	10.1		34.9	34.5	0.9

B	20.7	21.1	0.9		21.0	20.8	0.5
C	29.1	31.0	4.2		29.2	29.3	0.2
D	14.7	17.2	6.7		14.9	15.5	1.5
Distal RVD, mm	5.2±0.9	5.3±0.8	10.7	0.13	5.2±0.9	5.2±0.8	0.0
Chronic total occlusion	40.7	51.2	21.2	0.002	41.3	42.8	3.1
Lesion length, mm	146±98	160±101	13.8	0.042	147±98	149±95	2.0
PACCS grade				0.93			
0 (no calcification)	36.8	38.7	3.9		37.4	35.7	3.5
1	22.1	18.6	8.8		21.7	21.7	0.0
2	13.3	16.2	8.0		13.5	14.0	1.5
3	10.5	7.7	9.9		10.3	11.3	3.3
4	17.2	18.9	4.4		17.1	17.2	0.3
Iliac revascularization	21.1	24.7	8.8	0.23	21.0	22.4	3.5
BTK runoff vessels				0.61			
None	9.9	10.7	2.7		9.6	11.8	7.0
1	29.2	27.5	3.8		29.3	27.2	4.6
2	43.7	42.0	3.4		43.9	41.5	5.0
3	17.3	19.8	6.7		17.1	19.5	6.2
(missing data)	0.4	1.3	10.2	0.31	0.4	0.3	0.2
IVUS use	63.5	42.5	43.1	<0.001	63.7	59.5	8.6

Abbreviations: BNS, bare nitinol stent; BTK, below the knee; IVUS, intravascular ultrasound; PACCS, peripheral arterial calcium scoring system; PTX, paclitaxel; RVD, reference vessel diameter; Std diff, standard difference; TASC II, TransAtlantic Inter-Society Consensus.

^aContinuous data are presented as the mean ± standard deviation; categorical data are given as the percentage.

^bDefined as estimated glomerular filtration rate <30 mL/min/1.73m².

Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions

Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 2. Baseline Characteristics of the Study Population Before and After Matching in the PTX-Coated vs Angioplasty Groups.^a

	Overall Population				Matched Population		
	PTX-Coated (n=285)	PTA (n=377)	Std Diff, %	p	PTX-Coated (n=197)	PTA (n=310)	Std Diff, %
Men	74.7	66.3	18.6	0.021	72.1	68.7	7.4
Age, y	73±8	73±9	3.6	0.64	73±8	73±8	0.3
Body mass index, kg/m ²	22.5±3.3	22.8±3.6	8.0	0.30	22.7±3.4	22.7±3.6	1.6
Hypertension	80.7	86.5	15.6	0.054	83.2	82.8	1.1
Diabetes mellitus	57.9	57.0	1.8	0.87	59.9	59.0	1.7
Dyslipidemia	58.9	57.8	2.3	0.81	57.9	58.7	1.6
Smoking	42.5	40.3	4.3	0.63	40.1	39.9	0.4
Chronic renal failure ^b	27.5	39.5	25.8	0.001	32.0	34.2	4.7
(missing data)	0.4	0.0	8.4	0.43	0.0	0.0	0.0
Regular dialysis	19.6	32.6	29.9	<0.001	24.4	27.0	6.0
Aspirin use	91.9	88.3	12.1	0.15	90.4	89.7	2.1
Thienopyridine use	84.6	69.8	35.8	<0.001	78.2	76.8	3.4
Cilostazol use	26.7	27.9	2.7	0.79	26.4	27.3	2.1
Anticoagulant use	10.2	13.3	9.6	0.28	9.6	12.2	8.1
Rutherford category				0.98			
2	33.0	33.4	0.9		33.5	33.1	0.8
3	61.4	60.2	2.4		61.4	60.5	1.8
4	5.6	6.4	3.2		5.1	6.3	5.4
Ankle-brachial index	0.62±0.21	0.67±0.22	24.3	0.002	0.64±0.21	0.65±0.22	3.2
(missing data)	0.7	0.3	6.3	0.58	0.5	0.5	0.0
TASC II classification				<0.001			
A	35.4	63.4	58.2		45.2	46.8	3.2

B	20.7	10.3	28.9		18.3	16.1	5.8
C	29.1	21.8	17.0		27.4	29.5	4.6
D	14.7	4.5	35.2		9.1	7.6	5.5
Distal RVD, mm	5.2±0.9	5.0±0.9	27.4	0.001	5.1±0.9	5.1±0.9	1.3
Chronic total occlusion	40.7	15.1	59.5	<0.001	28.9	24.7	9.6
Lesion length, mm	146±98	104±97	43.6	<0.001	128±93	131±105	3.4
PACCS grade				0.006			
0 (no calcification)	36.8	30.2	14.0		35.0	32.8	4.6
1	22.1	17.5	11.6		20.8	21.1	0.6
2	13.3	15.6	6.6		14.7	15.8	2.9
3	10.5	11.7	3.6		11.2	9.9	4.0
4	17.2	24.9	19.1		18.3	20.4	5.3
Iliac revascularization	21.1	25.7	11.1	0.17	23.4	24.8	3.4
BTK runoff vessels				0.74			
None	9.9	13.2	10.4		10.7	12.9	6.7
1	29.2	26.1	7.0		29.1	27.7	3.1
2	43.7	43.5	0.2		44.9	42.6	4.6
3	17.3	17.2	0.1		15.3	16.8	4.2
(missing data)	0.4	1.3	10.7	0.24	0.5	0.5	0.7
IVUS use	63.5	39.8	48.9	<0.001	52.3	49.3	6.0

Abbreviations: BTK, below the knee; IVUS, intravascular ultrasound; PACCS, peripheral arterial calcium scoring system; PTA, angioplasty; PTX, paclitaxel; RVD, reference vessel diameter; Std diff, standard difference; TASC II, TransAtlantic Inter-Society Consensus.

^aContinuous data are presented as the mean ± standard deviation; categorical data are given as the percentage.

^bDefined as estimated glomerular filtration rate <30 mL/min/1.73m².

Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 3. Interaction Effect on Association of Paclitaxel-Coated Stent Use With Mortality Risk in PTX-Coated vs Bare Nitinol Stent Groups.

	Hazard Ratio (95% CI)	P for interaction
Overall (n=1158)	0.90 (0.67 to 1.22), p=0.50	
Sex		
Female (n=322)	0.89 (0.50 to 1.58), p=0.69	0.96
Male (n=836)	0.91 (0.63 to 1.30), p=0.59	
Age, y		
<73 (n=558)	1.09 (0.69 to 1.72), p=0.72	0.27
≥73 (n=600)	0.78 (0.52 to 1.16), p=0.22	
Body mass index, kg/m ²		
<22.5 (n=572)	1.12 (0.76 to 1.65), p=0.56	0.10
≥22.5 (n=586)	0.67 (0.41 to 1.10), p=0.11	
Hypertension		
No (n=185)	0.86 (0.39 to 1.91), p=0.72	0.91
Yes (n=973)	0.90 (0.65 to 1.26), p=0.55	
Diabetes mellitus		
No (n=535)	0.87 (0.53 to 1.42), p=0.57	0.86
Yes (n=623)	0.92 (0.62 to 1.35), p=0.66	
Dyslipidemia		
No (n=509)	0.87 (0.56 to 1.34), p=0.52	0.86
Yes (n=649)	0.92 (0.60 to 1.41), p=0.69	
Smoking		
No (n=669)	0.91 (0.61 to 1.35), p=0.63	0.99
Yes (n=489)	0.91 (0.57 to 1.45), p=0.69	
Chronic renal failure ^a		
No (n=826)	0.65 (0.42 to 1.02), p=0.062	0.042
Yes (n=331)	1.21 (0.80 to 1.85), p=0.37	
Regular dialysis		
No (n=904)	0.73 (0.49 to 1.09), p=0.12	0.048
Yes (n=254)	1.34 (0.84 to 2.15), p=0.22	
Aspirin use		
No (n=108)	0.00 (0.00 to >100), p=0.99	0.99
Yes (n=1050)	0.92 (0.67 to 1.25), p=0.59	
Thienopyridine use		
No (n=285)	0.75 (0.34 to 1.66), p=0.48	0.62
Yes (n=873)	0.93 (0.67 to 1.31), p=0.68	

Cilostazol use		
No (n=791)	0.94 (0.66 to 1.34), p=0.74	0.62
Yes (n=367)	0.79 (0.42 to 1.47), p=0.45	
Anticoagulant use		
No (n=1001)	0.92 (0.65 to 1.29), p=0.63	0.64
Yes (n=157)	0.76 (0.37 to 1.57), p=0.46	
Rutherford category		
2,3 (n=1066)	0.90 (0.65 to 1.25), p=0.53	0.99
4 (n=92)	0.90 (0.31 to 2.62), p=0.85	
Ankle-brachial index		
<0.66 (n=560)	0.82 (0.55 to 1.23), p=0.34	0.50
≥0.66 (n=595)	1.01 (0.64 to 1.59), p=0.97	
TASC II class		
A–C (n=966)	0.95 (0.68 to 1.32), p=0.74	0.46
D (n=192)	0.68 (0.30 to 1.53), p=0.35	
Distal RVD, mm		
<5.1 (n=563)	1.04 (0.71 to 1.53), p=0.84	0.22
≥5.1 (n=595)	0.71 (0.43 to 1.17), p=0.18	
Chronic total occlusion		
No (n=595)	0.84 (0.56 to 1.26), p=0.40	0.57
Yes (n=563)	1.00 (0.63 to 1.57), p=0.99	
Lesion length, mm		
<120 (n=579)	1.00 (0.68 to 1.48), p=1.00	0.41
≥120 (n=579)	0.78 (0.48 to 1.26), p=0.31	
PACSS grade		
0 (n=443)	0.44 (0.20 to 0.96), p=0.039	0.048
1–4 (n=715)	1.02 (0.73 to 1.43), p=0.90	
Iliac revascularization		
No (n=882)	0.90 (0.63 to 1.29), p=0.57	0.96
Yes (n=276)	0.92 (0.51 to 1.65), p=0.77	
BTK runoff vessels		
<2 (n=440)	0.91 (0.58 to 1.41), p=0.67	0.99
≥2 (n=706)	0.91 (0.60 to 1.38), p=0.64	
IVUS use		
No (n=606)	1.00 (0.67 to 1.48), p=0.99	0.45
Yes (n=552)	0.79 (0.49 to 1.27), p=0.33	

Abbreviations: BTK, below the knee; CI, confidence interval; IVUS, intravascular ultrasound; PACCS, peripheral arterial calcium scoring system; PTX, paclitaxel; RVD, reference vessel diameter; TASC, TransAtlantic Inter-Society Consensus;

^aDefined as estimated glomerular filtration rate <30 mL/min/1.73m².

Bold p values indicate statistical significance.

Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 4. Interaction Effect on Association of Paclitaxel-Coated Stent Use With Mortality Risk in PTX-Coated vs vs Angioplasty Groups.

	Hazard Ratio (95% CI)	P for interaction
Overall (n=662)	1.06 (0.73 to 1.55), p=0.75	
Sex		
Female (n=199)	1.19 (0.61 to 2.34), p=0.61	0.69
Male (n=463)	1.02 (0.64 to 1.62), p=0.94	
Age, y		
<73 (n=305)	1.11 (0.63 to 1.97), p=0.72	0.85
≥73 (n=357)	1.03 (0.62 to 1.72), p=0.90	
Body mass index, kg/m ²		
<22.5 (n=327)	1.23 (0.76 to 1.97), p=0.40	0.25
≥22.5 (n=335)	0.79 (0.42 to 1.49), p=0.47	
Hypertension		
No (n=106)	0.74 (0.29 to 1.86), p=0.52	0.39
Yes (n=556)	1.14 (0.74 to 1.75), p=0.56	
Diabetes mellitus		
No (n=282)	1.18 (0.64 to 2.18), p=0.60	0.64
Yes (n=380)	0.99 (0.61 to 1.60), p=0.96	
Dyslipidemia		
No (n=276)	1.19 (0.69 to 2.05), p=0.53	0.55
Yes (n=386)	0.96 (0.57 to 1.62), p=0.89	
Smoking		
No (n=389)	1.00 (0.62 to 1.63), p=0.99	0.63
Yes (n=273)	1.20 (0.65 to 2.19), p=0.56	
Chronic renal failure ^a		
No (n=434)	0.80 (0.45 to 1.41), p=0.43	0.15
Yes (n=227)	1.34 (0.81 to 2.22), p=0.25	
Regular dialysis		
No (n=483)	0.87 (0.52 to 1.48), p=0.61	0.21
Yes (n=179)	1.37 (0.80 to 2.35), p=0.25	
Aspirin use		
No (n=67)	0.00 (0.00 to >100), p=0.99	0.99
Yes (n=595)	1.14 (0.75 to 1.71), p=0.54	
Thienopyridine use		
No (n=158)	1.49 (0.60 to 3.73), p=0.39	0.41
Yes (n=504)	0.98 (0.64 to 1.52), p=0.94	

Cilostazol use		
No (n=481)	1.23 (0.78 to 1.93), p=0.38	0.18
Yes (n=181)	0.71 (0.34 to 1.47), p=0.36	
Anticoagulant use		
No (n=583)	1.03 (0.67 to 1.57), p=0.91	0.57
Yes (n=79)	1.35 (0.55 to 3.32), p=0.52	
Rutherford category		
2,3 (n=622)	1.02 (0.67 to 1.54), p=0.92	0.39
4 (n=40)	2.01 (0.44 to 9.19), p=0.37	
Ankle-brachial index		
<0.66 (n=327)	1.07 (0.62 to 1.84), p=0.80	0.99
≥0.66 (n=332)	1.06 (0.62 to 1.83), p=0.82	
TASC II class		
A–C (n=603)	1.02 (0.67 to 1.54), p=0.93	0.33
D (n=59)	2.97 (0.36 to 24.7), p=0.31	
Distal RVD, mm		
<5.1 (n=262)	1.16 (0.68 to 1.98), p=0.59	0.66
≥5.1 (n=400)	0.99 (0.58 to 1.70), p=0.98	
Chronic total occlusion		
No (n=489)	0.98 (0.62 to 1.56), p=0.95	0.49
Yes (n=173)	1.37 (0.59 to 3.16), p=0.46	
Lesion length, mm		
<120 (n=327)	1.00 (0.58 to 1.75), p=0.99	0.81
≥120 (n=335)	1.10 (0.64 to 1.90), p=0.73	
PACSS grade		
0 (n=219)	0.43 (0.17 to 1.06), p=0.067	0.024
1–4 (n=443)	1.28 (0.83 to 1.97), p=0.26	
Iliac revascularization		
No (n=505)	1.08 (0.68 to 1.72), p=0.74	0.89
Yes (n=157)	1.02 (0.51 to 2.05), p=0.95	
BTK runoff vessels		
<2 (n=257)	1.02 (0.60 to 1.75), p=0.94	0.89
≥2 (n=399)	1.07 (0.63 to 1.83), p=0.79	
IVUS use		
No (n=331)	1.30 (0.80 to 2.11), p=0.28	0.15
Yes (n=331)	0.75 (0.40 to 1.40), p=0.36	

Abbreviations: BTK, below the knee; CI, confidence interval; IVUS, intravascular ultrasound; PACCS, peripheral arterial calcium scoring system; PTX, paclitaxel; RVD, reference vessel diameter; TASC, TransAtlantic Inter-Society Consensus;

^aDefined as estimated glomerular filtration rate <30 mL/min/1.73m².

Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions

Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 5. Interaction Effect of Paclitaxel Dose on Association of Paclitaxel-Coated Stent Use With Mortality Risk in PTX-Coated vs Bare Nitinol Stent Groups.^a

	Crude Model	Multivariable Model	PS-Matched Model	PS-Stratified Model
Paclitaxel-coated stent use	0.77 (0.57 to 1.03), p=0.081	0.81 (0.59 to 1.10), p=0.18	0.81 (0.57 to 1.15), p=0.25	0.90 (0.66 to 1.23), p=0.51
Paclitaxel dose (vs none), µg				
Q1 (<552)	0.31 (0.12 to 0.83), p=0.020	0.49 (0.18 to 1.36), p=0.17	0.27 (0.08 to 0.92), p=0.036	0.40 (0.15 to 1.09), p=0.073
Q2 (552 to 1103)	0.82 (0.48 to 1.38), p=0.44	0.68 (0.39 to 1.20), p=0.18	0.74 (0.34 to 1.61), p=0.44	0.96 (0.56 to 1.64), p=0.89
Q3 (1103 to 2251)	0.93 (0.60 to 1.45), p=0.76	0.92 (0.59 to 1.45), p=0.73	1.14 (0.66 to 1.97), p=0.64	1.07 (0.68 to 1.67), p=0.78
Q4 (≥2251)	0.84 (0.50 to 1.42), p=0.51	0.95 (0.54 to 1.70), p=0.87	0.85 (0.44 to 1.65), p=0.63	0.92 (0.54 to 1.58), p=0.77

Abbreviations: PS, propensity score; PTX, paclitaxel; Q, quartile.

^aData are presented as the hazard ratio (95% confidence interval), p value.

Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions

Tomonori Katsuki et al. *J Endovasc Ther.* 2019;26(5).

Supplementary Table 6. Interaction Effect of Paclitaxel Dose on Association of Paclitaxel-Coated Stent Use With Mortality Risk in PTX-Coated vs Angioplasty Groups.

	Crude Model	Multivariate Model	PS-Matched Model	PS-Stratified Model
Paclitaxel-coated stent use	0.89 (0.63 to 1.26), p=0.50	1.01 (0.68 to 1.51), p=0.94	0.98 (0.60 to 1.61), p=0.95	1.06 (0.71 to 1.59), p=0.76
Paclitaxel dose (vs none), µg				
Q1 (<552)	0.36 (0.13 to 0.98), p=0.046	0.69 (0.24 to 1.97), p=0.49	0.21 (0.03 to 1.75), p=0.15	0.43 (0.16 to 1.20), p=0.11
Q2 (552 to 1103)	0.94 (0.54 to 1.64), p=0.83	0.93 (0.51 to 1.71), p=0.83	0.92 (0.44 to 1.93), p=0.82	1.07 (0.60 to 1.88), p=0.83
Q3 (1103 to 2251)	1.08 (0.67 to 1.74), p=0.75	1.07 (0.63 to 1.83), p=0.79	1.54 (0.65 to 3.66), p=0.33	1.38 (0.81 to 2.37), p=0.23
Q4 (≥2251)	0.96 (0.55 to 1.68), p=0.90	1.67 (0.75 to 3.73), p=0.21	1.19 (0.29 to 4.82), p=0.81	1.37 (0.70 to 2.69), p=0.35

Abbreviations: PS, propensity score; PTX, paclitaxel; Q, quartile.

^aData are presented as the hazard ratio (95% confidence interval), p value.

